High-throughput glycosylation analysis of therapeutic immunoglobulin G by capillary gel electrophoresis using a DNA analyzer.

Abstract:

:The Fc glycosylation of therapeutic antibodies is crucial for their effector functions and their behavior in pharmacokinetics and pharmacodynamics. To monitor the Fc glycosylation in bioprocess development and characterization,high-throughput techniques for glycosylation analysis are needed. Here, we describe the development of a largely automated high-throughput glycosylation profiling method with multiplexing capillary-gel-electrophoresis (CGE) with laser induced fluorescence (LIF) detection using a DNA analyzer. After PNGaseF digestion, the released glycans were labeled with 9-aminopyrene-1,3,6-trisulfonic acid (APTS) in 96-well plates, which was followed by the simultaneous analysis of up to 48 samples. The peak assignment was conducted by HILIC-UPLC-MS/MS of the APTS-labeled glycans combined with peak fractionation and subsequent CGE-LIF analysis of the MS-characterized fractions. Quantitative data evaluation of the various IgG glycans was performed automatically using an in-house developed software solution. The excellent method accuracy and repeatability of the test system was verified by comparison with two UPLC-based methods for glycan analysis. Finally, the practical value of the developed method was demonstrated by analyzing the antibody glycosylation profiles from fermentation broths after small scale protein A purification.

journal_name

MAbs

journal_title

mAbs

authors

Reusch D,Haberger M,Kailich T,Heidenreich AK,Kampe M,Bulau P,Wuhrer M

doi

10.4161/mabs.26712

subject

Has Abstract

pub_date

2014-01-01 00:00:00

pages

185-96

issue

1

eissn

1942-0862

issn

1942-0870

pii

26712

journal_volume

6

pub_type

杂志文章

相关文献

mAbs文献大全
  • Effective binding to protein antigens by antibodies from antibody libraries designed with enhanced protein recognition propensities.

    abstract::Antibodies provide immune protection by recognizing antigens of diverse chemical properties, but elucidating the amino acid sequence-function relationships underlying the specificity and affinity of antibody-antigen interactions remains challenging. We designed and constructed phage-displayed synthetic antibody librar...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.1080/19420862.2018.1550320

    authors: Jian JW,Chen HS,Chiu YK,Peng HP,Tung CP,Chen IC,Yu CM,Tsou YL,Kuo WY,Hsu HJ,Yang AS

    更新日期:2019-02-01 00:00:00

  • Rational identification of an optimal antibody mixture for targeting the epidermal growth factor receptor.

    abstract::The epidermal growth factor receptor (EGFR) is frequently dysregulated in human malignancies and a validated target for cancer therapy. Two monoclonal anti-EGFR antibodies (cetuximab and panitumumab) are approved for clinical use. However, the percentage of patients responding to treatment is low and many patients exp...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.4161/mabs.3.6.17955

    authors: Koefoed K,Steinaa L,Søderberg JN,Kjær I,Jacobsen HJ,Meijer PJ,Haurum JS,Jensen A,Kragh M,Andersen PS,Pedersen MW

    更新日期:2011-11-01 00:00:00

  • Specific and high-resolution identification of monoclonal antibody fragments detected by capillary electrophoresis-sodium dodecyl sulfate using reversed-phase HPLC with top-down mass spectrometry analysis.

    abstract::In recent years, capillary electrophoresis-sodium dodecyl sulfate (cSDS) has been widely used for high resolution separation and quantification of the fragments and aggregates of monoclonal antibodies (mAbs) to ensure the quality of mAb therapeutics. However, identification of the low-molecular-weight (LMW) and high-m...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.1080/19420862.2019.1646554

    authors: Wang WH,Cheung-Lau J,Chen Y,Lewis M,Tang QM

    更新日期:2019-10-01 00:00:00

  • Delivery of ALX-0171 by inhalation greatly reduces respiratory syncytial virus disease in newborn lambs.

    abstract::Respiratory syncytial virus (RSV) is a common cause of acute lower respiratory disease in infants and young children worldwide. Currently, treatment is supportive and no vaccines are available. The use of newborn lambs to model hRSV infection in human infants may provide a valuable tool to assess safety and efficacy o...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.1080/19420862.2018.1470727

    authors: Larios Mora A,Detalle L,Gallup JM,Van Geelen A,Stohr T,Duprez L,Ackermann MR

    更新日期:2018-07-01 00:00:00

  • Improved in vitro and in vivo activity against CD303-expressing targets of the chimeric 122A2 antibody selected for specific glycosylation pattern.

    abstract::Plasmacytoid dendritic cells (pDCs) play a central role for both innate and adaptive antiviral responses, as they direct immune responses through their unique ability to produce substantial concentrations of type I interferon (IFNs) upon viral encounter while also activating multiple immune cells, including macrophage...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.1080/19420862.2018.1451283

    authors: Fournier N,Jacque E,Fontayne A,Derache D,Dupont G,Verhaeghe L,Baptista L,Dehenne A,Dezetter AS,Terrier A,Longue A,Pochet-Beghin V,Beghin C,Chtourou S,de Romeuf C

    更新日期:2018-05-01 00:00:00

  • Homology modeling and structure-based design improve hydrophobic interaction chromatography behavior of integrin binding antibodies.

    abstract::Monoclonal antibody (mAb) candidates from high-throughput screening or binding affinity optimization often contain mutations leading to liabilities for further development of the antibody, such as aggregation-prone regions and lack of solubility. In this work, we optimized a candidate integrin α11-binding mAb for deve...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.1080/19420862.2018.1475871

    authors: Jetha A,Thorsteinson N,Jmeian Y,Jeganathan A,Giblin P,Fransson J

    更新日期:2018-08-01 00:00:00

  • Comparative clinical pharmacokinetics of antibody-drug conjugates in first-in-human Phase 1 studies.

    abstract::Although there are currently more than 30 antibody-drug conjugates (ADC) in clinical development for the treatment of blood cancers and solid tumors, comparison of their clinical pharmacokinetics (PK) is challenging because of the large number of, and differences between, the targets, ADC constructs, dosing regimens, ...

    journal_title:mAbs

    pub_type: 杂志文章,评审

    doi:10.4161/mabs.28965

    authors: Deslandes A

    更新日期:2014-07-01 00:00:00

  • Concentrations of EpCAM ectodomain as found in sera of cancer patients do not significantly impact redirected lysis and T-cell activation by EpCAM/CD3-bispecific BiTE antibody MT110.

    abstract::Ectodomains of target antigens for antibody-based therapies can be shed from the target cell surface and found in sera of patients. Shed ectodomains of therapeutic targets not only pose the risk of sequestering therapeutic antibodies but, in a multimeric form, of triggering T cell activation by bispecific antibodies b...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.4161/mabs.3.1.14193

    authors: Petsch S,Gires O,Rüttinger D,Denzel S,Lippold S,Baeuerle PA,Wolf A

    更新日期:2011-01-01 00:00:00

  • Biosimilars in oncology and inflammatory diseases: current and future considerations for clinicians in Latin America.

    abstract::Biological therapies have revolutionized the treatment of several cancers and systemic immune-mediated inflammatory conditions. Expiry of patents protecting a number of biologics has provided the opportunity to commercialize highly similar versions, known as biosimilars. Biosimilars are approved by regulatory agencies...

    journal_title:mAbs

    pub_type: 杂志文章,评审

    doi:10.1080/19420862.2018.1484977

    authors: Scheinberg M,Pineda C,Castañeda-Hernández G,Zarbá JJ,Damião A,Arantes LH Jr,Jacobs I

    更新日期:2018-08-01 00:00:00

  • Fluorescent Citrine-IgG fusion proteins produced in mammalian cells.

    abstract::Genetically encoded fluorescent antibodies are desirable for many applications in biotechnology, proteomics, microscopy, cell biology and molecular diagnostics, although efficient production of fluorescent IgGs in mammalian cells has been hampered by different and mutually incompatible secretion- and folding-requireme...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.4161/mabs.2.6.13179

    authors: Haas AK,von Schwerin C,Matscheko D,Brinkmann U

    更新日期:2010-11-01 00:00:00

  • Immunotherapy for Alzheimer disease.

    abstract::Immunotherapy approaches for Alzheimer disease currently are among the leading therapeutic directions for the disease. Active and passive immunotherapy against the beta-amyloid peptides that aggregate and accumulate in the brain of those afflicted by the disease have been shown by numerous groups to reduce plaque path...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.4161/mabs.1.2.7829

    authors: Gouras GK

    更新日期:2009-03-01 00:00:00

  • An efficient method for variable region assembly in the construction of scFv phage display libraries using independent strand amplification.

    abstract::Phage display library technology is a common method to produce human antibodies. In this technique, the immunoglobulin variable regions are displayed in a bacteriophage in a way that each filamentous virus displays the product of a single antibody gene on its surface. From the collection of different phages, it is pos...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.4161/mabs.20653

    authors: Sotelo P,Collazo N,Zuñiga R,Gutiérrez-González M,Catalán D,Ribeiro CH,Aguillón JC,Molina MC

    更新日期:2012-07-01 00:00:00

  • Discovery of high affinity anti-ricin antibodies by B cell receptor sequencing and by yeast display of combinatorial VH:VL libraries from immunized animals.

    abstract::Ricin is a toxin that could potentially be used as a bioweapon. We identified anti-ricin A chain antibodies by sequencing the antibody repertoire from immunized mice and by selecting high affinity antibodies using yeast surface display. These methods led to the isolation of multiple antibodies with high (sub-nanomolar...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.1080/19420862.2016.1190059

    authors: Wang B,Lee CH,Johnson EL,Kluwe CA,Cunningham JC,Tanno H,Crooks RM,Georgiou G,Ellington AD

    更新日期:2016-08-01 00:00:00

  • High throughput functional epitope mapping: revisiting phage display platform to scan target antigen surface.

    abstract::Antibody engineering must be accompanied by mapping strategies focused on identifying the epitope recognized by each antibody to define its unique functional identity. High throughput fine specificity determination remains technically challenging. We review recent experiences aimed at revisiting the oldest and most ex...

    journal_title:mAbs

    pub_type: 杂志文章,评审

    doi:10.4161/mabs.36144

    authors: Rojas G,Tundidor Y,Infante YC

    更新日期:2014-01-01 00:00:00

  • Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates.

    abstract::Antibody-drug conjugates (ADCs) represent a new class of cancer therapeutics. Their design involves a tumor-specific antibody, a linker and a cytotoxic payload. They were designed to allow specific targeting of highly potent cytotoxic agents to tumor cells whilst sparing normal cells. Frequent toxicities that may be d...

    journal_title:mAbs

    pub_type: 杂志文章,评审

    doi:10.1080/19420862.2016.1156829

    authors: Donaghy H

    更新日期:2016-05-01 00:00:00

  • A novel human monoclonal antibody specific to the A33 glycoprotein recognizes colorectal cancer and inhibits metastasis.

    abstract::Colorectal cancer represents the second most common cause of cancer-related death. The human A33 transmembrane glycoprotein is a validated tumor-associated antigen, expressed in 95% of primary and metastatic colorectal cancers. Using phage display technology, we generated a human monoclonal antibody (termed A2) specif...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.1080/19420862.2020.1714371

    authors: Murer P,Plüss L,Neri D

    更新日期:2020-01-01 00:00:00

  • Lepidopteran cells, an alternative for the production of recombinant antibodies?

    abstract::Monoclonal antibodies are used with great success in many different therapeutic domains. In order to satisfy the growing demand and to lower the production cost of these molecules, many alternative systems have been explored. Among them, the baculovirus/insect cells system is a good candidate. This system is very safe...

    journal_title:mAbs

    pub_type: 杂志文章,评审

    doi:10.4161/mabs.19942

    authors: Cérutti M,Golay J

    更新日期:2012-05-01 00:00:00

  • Characterizing monoclonal antibody structure by carboxyl group footprinting.

    abstract::Structural characterization of proteins and their antigen complexes is essential to the development of new biologic-based medicines. Amino acid-specific covalent labeling (CL) is well suited to probe such structures, especially for cases that are difficult to examine by alternative means due to size, complexity, or in...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.1080/19420862.2015.1023683

    authors: Kaur P,Tomechko SE,Kiselar J,Shi W,Deperalta G,Wecksler AT,Gokulrangan G,Ling V,Chance MR

    更新日期:2015-01-01 00:00:00

  • Autoantibody depletion ameliorates disease in murine experimental autoimmune encephalomyelitis.

    abstract::Much data support a role for central nervous system antigen-specific antibodies in the pathogenesis of multiple sclerosis (MS). The effects of inducing a decrease in (auto)antibody levels on MS or experimental autoimmune encephalomyelitis (EAE) through specific blockade of FcRn, however, remain unexplored. We recently...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.4161/mabs.25439

    authors: Challa DK,Bussmeyer U,Khan T,Montoyo HP,Bansal P,Ober RJ,Ward ES

    更新日期:2013-09-01 00:00:00

  • Differences in N-glycan structures found on recombinant IgA1 and IgA2 produced in murine myeloma and CHO cell lines.

    abstract::The development and production of recombinant monoclonal antibodies is well established. Although most of these are IgGs, there is also great interest in producing recombinant IgAs since this isotype plays a critical role in providing immunologic protection at mucosal surfaces. The choice of expression system for prod...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.4161/mabs.2.3.11802

    authors: Yoo EM,Yu LJ,Wims LA,Goldberg D,Morrison SL

    更新日期:2010-05-01 00:00:00

  • Pharmacokinetic properties of IgG and various Fc fusion proteins in mice.

    abstract::Fusion to an IgG Fc region is an established strategy to extend the half-life of therapeutic proteins. Most Fc fusion proteins, however, do not achieve the long half-life of IgGs. Based on findings that scFv-Fc fusion proteins exhibit a shorter half-life than the corresponding IgG molecules, we performed a comparative...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.1080/19420862.2015.1113360

    authors: Unverdorben F,Richter F,Hutt M,Seifert O,Malinge P,Fischer N,Kontermann RE

    更新日期:2016-01-01 00:00:00

  • A method to confer Protein L binding ability to any antibody fragment.

    abstract::Recombinant antibody single-chain variable fragments (scFv) are difficult to purify homogeneously from a protein complex mixture. The most effective, specific and fastest method of purification is an affinity chromatography on Protein L (PpL) matrix. This protein is a multi-domain bacterial surface protein that is abl...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.1080/19420862.2015.1116657

    authors: Lakhrif Z,Pugnière M,Henriquet C,di Tommaso A,Dimier-Poisson I,Billiald P,Juste MO,Aubrey N

    更新日期:2016-01-01 00:00:00

  • CD40- and CD95-specific antibody single chain-Baff fusion proteins display BaffR-, TACI- and BCMA-restricted agonism.

    abstract::Antibodies that target a clinically relevant group of receptors within the tumor necrosis factor receptor superfamily (TNFRSF), including CD40 and CD95 (Fas/Apo-1), also require binding to Fc gamma receptors (FcγRs) to elicit a strong agonistic activity. This FcγR dependency largely relies on the mere cellular anchori...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.1080/19420862.2020.1807721

    authors: Nelke J,Medler J,Weisenberger D,Beilhack A,Wajant H

    更新日期:2020-01-01 00:00:00

  • Antibodies to watch in 2010.

    abstract::Monoclonal antibodies (mAbs) are a burgeoning class of therapeutics, with more than 25 approved in countries worldwide. Novel molecules are entering clinical study at a rate of nearly 40 per year, and the commercial pipeline includes approximately 240 mAb therapeutics in clinical studies that have not yet progressed t...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.4161/mabs.2.1.10677

    authors: Reichert JM

    更新日期:2010-01-01 00:00:00

  • Selection and verification of antibodies against the cytoplasmic domain of M2 of influenza, a transmembrane protein.

    abstract::Interactions between the cytoplasmic domains of viral transmembrane proteins and host machinery often determine the outcome of viral infection. The M2 protein of influenza A has been identified as a key player in autophagy-mediated viral replication. Here, we describe the engineering and validation of an antibody spec...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.1080/19420862.2020.1843754

    authors: Velappan N,Micheva-Viteva S,Adikari SH,Waldo GS,Lillo AM,Bradbury ARM

    更新日期:2020-01-01 00:00:00

  • Effects of the FcRn developmental pharmacology on the pharmacokinetics of therapeutic monoclonal IgG antibody in pediatric subjects using minimal physiologically-based pharmacokinetic modelling.

    abstract::The aim of this study was to investigate neonatal Fc receptor (FcRn) concentration developmental pharmacology in adult and pediatric subjects using minimal physiologically-based pharmacokinetic (mPBPK) modelling. Three types of pharmacokinetic (PK) data for three agents (endogenous/exogenous native IgG, bevacizumab an...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.1080/19420862.2018.1494479

    authors: Hardiansyah D,Ng CM

    更新日期:2018-10-01 00:00:00

  • In vitro and in vivo modifications of recombinant and human IgG antibodies.

    abstract::Tremendous knowledge has been gained in the understanding of various modifications of IgG antibodies, driven mainly by the fact that antibodies are one of the most important groups of therapeutic molecules and because of the development of advanced analytical techniques. Recombinant monoclonal antibody (mAb) therapeut...

    journal_title:mAbs

    pub_type: 杂志文章,评审

    doi:10.4161/mabs.29883

    authors: Liu H,Ponniah G,Zhang HM,Nowak C,Neill A,Gonzalez-Lopez N,Patel R,Cheng G,Kita AZ,Andrien B

    更新日期:2014-01-01 00:00:00

  • Characterization of monoclonal antibody's binding kinetics using oblique-incidence reflectivity difference approach.

    abstract::Monoclonal antibodies (mAbs) against human proteins are the primary protein capture reagents for basic research, diagnosis, and molecular therapeutics. The 2 most important attributes of mAbs used in all of these applications are their specificity and avidity. While specificity of a mAb raised against a human protein ...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.4161/19420862.2014.985919

    authors: Liu S,Zhang H,Dai J,Hu S,Pino I,Eichinger DJ,Lyu H,Zhu H

    更新日期:2015-01-01 00:00:00

  • A chemical and computational approach to comprehensive glycation characterization on antibodies.

    abstract::Non-enzymatic glycation is a challenging post-translational modification to characterize due to the structural heterogeneity it generates in proteins. Glycation has become increasingly recognized as an important product quality attribute to monitor, particularly for the biotechnology sector, which produces recombinant...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.1080/19420862.2015.1046663

    authors: Saleem RA,Affholter BR,Deng S,Campbell PC,Matthies K,Eakin CM,Wallace A

    更新日期:2015-01-01 00:00:00

  • A two-in-one antibody engineered from a humanized interleukin 4 antibody through mutation in heavy chain complementarity-determining regions.

    abstract::A mono-specific antibody may recruit a second antigen binding specificity, thus converting to a dual-specific Two-in-One antibody through mutation at the light chain complementarity-determining regions (CDRs). It is, however, unknown whether mutation at the heavy chain CDRs may evolve such dual specificity. Herein, we...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.4161/mabs.28483

    authors: Lee CV,Koenig P,Fuh G

    更新日期:2014-05-01 00:00:00